Brief: Akari Therapeutics To Present Oral Abstract At SITC’S 40th Annual Meeting
03/10/2025 15:05
Oct 3 (Reuters) - Akari Therapeutics PLC AKTX.O: AKARI THERAPEUTICS ANNOUNCES ABSTRACT ACCEPTED FOR ORAL PRESENTATION AT THE 40TH ANNUAL SOCIETY FOR IMMUNOTHERAPY OF CANCER (SITC) MEETING Source text: ID:nGNX8PZ17j Further company coverage: AKTX.O ((Reuters.Briefs@thomsonreuters.com;))
Recent news on Akari Therapeutics
See all newsBrief: Akari Therapeutics - Aktx-101 Demonstrates Robust Anti-Tumor Activity In Urothelial Cancer Preclinical Models
UK's Akari Therapeutics Q2 net loss widens on higher R&D for AKTX-101
Akari Therapeutics PLC reports results for the quarter ended June 30 - Earnings Summary
Akari Therapeutics PLC expected to post a loss of $1.40 a share - Earnings Preview
Brief: Akari Therapeutics Enters Strategic Research Collaboration With Whitehawk Therapeutics